Marinus Charts The Way Forward For Ganaxolone Amid Business Challenges
Phase II results for Marinus’s ganaxolone in postpartum depression are a mixed bag, but the US biotech sees potential in this and other neurological indications, probably with partners.
You may also be interested in...
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
The biotech announces another poor performance for its lead drug candidate, but puts a positive spin on the data and plans continued development.
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.